Shareholder Update: Creative Medical Technology Ho
Post# of 350
(Total Views: 231)
Posted On: 04/23/2018 12:23:35 PM
Shareholder Update: Creative Medical Technology Holdings, Inc. Continues To Extinguish Debt
NEWS PROVIDED BY
Creative Medical Technology Holdings, Inc.
12:19 ET
PHOENIX, April 23, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) announced today that additional debt in the amount of $332,000.00 has been extinguished.
As previously announced Creative Medical Technology Holdings, Inc. took on debt in order to advance our technologies and continue towards our goal of commercialization and cash flow.
"We continue to focus on the business at hand and our portfolio including issued patents for the treatment of erectile dysfunction, degenerative disc disease and our amniotic derived stem cell as well as patents pending in the area of neurological damage due to radiation toxicity and stroke amongst others," said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc.
As announced on March 26, 2018, we will be exhibiting at the American Urological Association conference in May 2018. We're excited to introduce CaverStemTM to a broad base of the urological community.
For those interested in the CaverStemTM procedure, please refer to our website at caverstem.com. Only physicians trained and approved for the CaverStemTM procedure are identified on our website.
https://www.prnewswire.com/news-releases/shar...34543.html
Aloha
NEWS PROVIDED BY
Creative Medical Technology Holdings, Inc.
12:19 ET
PHOENIX, April 23, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) announced today that additional debt in the amount of $332,000.00 has been extinguished.
As previously announced Creative Medical Technology Holdings, Inc. took on debt in order to advance our technologies and continue towards our goal of commercialization and cash flow.
"We continue to focus on the business at hand and our portfolio including issued patents for the treatment of erectile dysfunction, degenerative disc disease and our amniotic derived stem cell as well as patents pending in the area of neurological damage due to radiation toxicity and stroke amongst others," said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc.
As announced on March 26, 2018, we will be exhibiting at the American Urological Association conference in May 2018. We're excited to introduce CaverStemTM to a broad base of the urological community.
For those interested in the CaverStemTM procedure, please refer to our website at caverstem.com. Only physicians trained and approved for the CaverStemTM procedure are identified on our website.
https://www.prnewswire.com/news-releases/shar...34543.html
Aloha
(1)
(0)Creative Medical Technology Holdings Inc (CELZ) Stock Research Links
Scroll down for more posts ▼